慢性淋巴细胞白血病患者的静脉血栓栓塞:一项丹麦全国性队列研究
该研究基于丹麦全国慢性淋巴细胞白血病(CLL)登记库(2008-2015年)3609例患者,随访中位2.6年,共发生92例静脉血栓栓塞(VTE),总发病率为8.2/1000人年(95%CI 6.7-10.1)。既往VTE或第二原发癌与VTE风险显著相关(HR分别为5.09和3.72),而CLL不良预后标志物关联较弱;合并VTE的CLL患者死亡率略高,在<60岁患者中最明显(HR 7.74)。
要点
- CLL患者VTE总发病率为8.2/1000人年(95%CI 6.7-10.1),中位随访2.6年。
- 既往VTE(HR 5.09)或第二原发癌(HR 3.72)与VTE风险的相关性强于任何CLL特异性标志物。
- 合并VTE的CLL患者死亡率略高,<60岁患者HR为7.74(95%CI 2.12-28.29)。
核心结论
- 研究提示CLL不良预后标志物与VTE风险升高相关,但既往VTE或第二原发癌与VTE风险的关联强于任何CLL特异性标志物。
- 关注VTE这一可预防的并发症可能改善年轻CLL患者的生存。
研究设计与样本
- 丹麦全国CLL登记库(2008-2015年)队列研究,纳入3609例CLL患者,从CLL诊断日期随访至死亡、VTE、移居或行政删失。
- 采用Cox模型估计风险比(HR),并将第二原发癌和抗凝治疗作为时变暴露。
主要发现
- 中位随访2.6年期间,3609例CLL患者共发生92例VTE,总发病率为8.2/1000人年(95%CI 6.7-10.1)。
- 既往VTE史与VTE的HR为5.09(95%CI 2.82-9.17),第二原发癌与VTE的HR为3.72(95%CI 2.15-6.34)。
- β2微球蛋白>4 mg/L、免疫球蛋白HV未突变及不良细胞遗传学与VTE的HR较低。
- 合并VTE的CLL患者死亡率略高,在<60岁患者中最明显(HR 7.74;95%CI 2.12-28.29)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为关注VTE这一可预防的并发症可能改善年轻CLL患者的生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is associated with inferior survival in cancer patients. The risk of VTE and its effect on survival in chronic lymphocytic leukemia (CLL) patients remains unclear. The present study investigated the impact of patient-related factors, CLL prognostic markers, and CLL treatment on the risk of VTE and assessed overall survival relative to VTE. All patients in the Danish National CLL Registry (2008-2015) were followed from the date of CLL diagnosis to death, VTE, emigration, or administrative censoring. Hazard ratios (HRs) were estimated using Cox models, and second primary cancers and anticoagulation treatment were included as time-varying exposures. During a median follow-up of 2.6 years, 92 VTEs occurred among 3609 CLL patients, corresponding to a total incidence rate of 8.2 VTEs per 1000 person-years (95% confidence interval [CI], 6.7-10.1). A history of VTE or second primary cancer was associated with HRs of VTE of 5.09 (95% CI, 2.82-9.17) and 3.72 (95% CI, 2.15-6.34), respectively, while β2-microglobulin >4 mg/L, unmutated immunoglobulin HV and unfavorable cytogenetics had lower HRs. CLL patients with VTE had marginally higher mortality, which was most pronounced among patients <60 years of age (HR, 7.74; 95% CI, 2.12-28.29). Our findings suggest that markers of unfavorable CLL prognosis contribute to an increased risk of VTE; however, previous VTE or a second primary cancer is more strongly associated with the risk of VTE than any CLL-specific marker. Focusing attention on this preventable complication may improve survival in young CLL patients.
引用
- Gade IL, Riddersholm SJ, Christiansen I, et al. Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study. Blood Adv. 2018. PMID: 30425066. doi:10.1182/bloodadvances.2018023895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。